SciBX: Science-Business eXchange Contents: August 15 2013, Volume 6 / Issue 31

/p> TABLE OF CONTENTS August 15 2013, Volume 6 / Issue 31 Analysis Cover Story Translational Notes Targets and Mechanisms Tools The Distillery: Therapeutics Autoimmune disease Cancer Cardiovascular disease Endocrine/metabolic disease Gastrointestinal disease Neurology The Distillery: Techniques Assays and screens Disease models Drug platforms Advertisement Biopharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery The June 2013 issue of Biopharma Dealmakers showcases companies with partnering opportunities. This week, find out about how you can collaborate with Novozymes Biopharma. Nature Publishing Group and Relay Technology Management present: The Epigenetics Target Explorer  Click here to access this free online tool and the accompanying article in Nature Reviews Drug Discovery.    Analysis Cover Story Top B cell lymphoma and the microbiome Kai-Jye Lou doi:10.1038/scibx.2013.812 UC researchers have shown the gut microbiome is a key contributor to lymphoma risk and identified specific alterations to microbiome composition that could attenuate this risk. The group founded Microbio Pharma to develop and commercialize probiotics on the basis of the findings. Full Text | PDF Translational Notes Top Translational tidbits Lev Osherovich, C. Simone Fishburn and Kai-Jye Lou doi:10.1038/scibx.2013.813 The Scripps Research Institute has teamed up with Sigma-Aldrich to fast-track access to reagents emerging from Scripps labs; TTOs grapple with recent patent rulings; and a roundup of July's public-private partnerships shows a flurry of activity in Europe. Full Text | PDF Targets and Mechanisms Top IL-17 inhibitors: good news, bad news Michael J. Haas doi:10.1038/scibx.2013.814 Emerging research suggests companies developing inhibitors of IL-17A signaling have a repurposing opportunity and a new safety concern to navigate. Full Text | PDF Tools Top Chromosome shutdown Tracey Baas doi:10.1038/scibx.2013.815 A new technique to shut down chromosome 21 will reshape how Down syndrome is modeled and, in the longer term, could point to new disease targets or a strategy to remove the extra chromosome in patient cells. Full Text | PDF Distillery: Therapeutics Autoimmune disease Top Not applicable doi:10.1038/scibx.2013.816 Mouse studies identified a combination of 17 Clostridia strains (17-mix) that could help treat inflammatory bowel disease. Full Text | PDF Notch doi:10.1038/scibx.2013.817 Cell culture and mouse studies suggest the tocopherol derivative TFA-12 could help promote remyelination in MS. Full Text | PDF Cancer Top Unknown doi:10.1038/scibx.2013.818 Mouse studies suggest Lactobacillus johnsonii supplementation could help prevent ataxia-telangiectasia–associated B cell lymphomas. Full Text | PDF Polo-like kinase 4 (PLK4; STK18) doi:10.1038/scibx.2013.819 In vitro and mouse studies identified small molecule PLK4 inhibitors that could help treat breast cancer. Full Text | PDF Keratinocyte growth factor receptor (KGFR; FGFR2; CD332); tumor protein p63 (TP63; p63) doi:10.1038/scibx.2013.820 Cell culture and mouse studies suggest inhibiting FGFR2 could help treat squamous cell carcinoma (SCC). Full Text | PDF Cystathionine β-synthase (CBS) doi:10.1038/scibx.2013.821 In vitro and mouse studies suggest inhibiting CBS could help treat colorectal cancer. Full Text | PDF Core 1 synthase glycoprotein-N-acetylgalactosamine 3-β-galactosyltransferase 1 (C1GALT1) doi:10.1038/scibx.2013.822 Human tissue and mouse studies suggest inhibiting C1GALT1 could help treat hepatocellular carcinoma (HCC). Full Text | PDF DNA doi:10.1038/scibx.2013.823 In vitro and mouse studies suggest a new class of metal hydrides could help treat cancer. Full Text | PDF Notch 3 (NOTCH3) doi:10.1038/scibx.2013.824 Cell culture and mouse studies suggest inhibiting NOTCH3 could help treat lung cancer by eliminating tumor-propagating cells (TPCs). Full Text | PDF IL-17A; IL-17 receptor C (IL17RC); VEGF doi:10.1038/scibx.2013.825 Mouse studies suggest IL-17A inhibitors could help treat VEGF inhibitor–resistant cancers. Full Text | PDF Cardiovascular disease Top IL-17 doi:10.1038/scibx.2013.826 Studies in patient samples, human cell culture and mice suggest upregulation of IL-17 signaling could help reduce the risk of cardiovascular events. Full Text | PDF Endocrine/metabolic disease Top Complement component 1q subcomponent (C1Q); complement component 1q subcomponent A chain (C1QA) doi:10.1038/scibx.2013.827 Mouse studies suggest inhibiting C1Q signaling could help prevent obesity-associated metabolic impairments and metabolic syndrome. Full Text | PDF Gastrointestinal disease Top Calcium release–activated calcium channel (CRAC) doi:10.1038/scibx.2013.828 Cell culture studies suggest antagonizing CRAC could help treat acute pancreatitis. Full Text | PDF Neurology Top Histone deacetylase 3 (HDAC3); huntingtin (HTT) doi:10.1038/scibx.2013.829 Cell culture studies suggest HDAC3 inhibitors could help treat HD. Full Text | PDF Jumonji/ARID domain containing protein 1C (KDM5C; JARID1C) doi:10.1038/scibx.2013.830 Studies in patient samples, cultured cells and flies suggest inhibiting JARID1C could help to treat HD. Full Text | PDF NMDA receptor NR3A subtype (GRIN3A; NR3A); huntingtin (HTT) doi:10.1038/scibx.2013.831 Patient and mouse studies suggest inhibiting GRIN3A could help to prevent or delay HD progression. Full Text | PDF Adenosine A2A receptor (ADORA2A); ecto-5′-nucleotidase (NT5E; NT; CD73) doi:10.1038/scibx.2013.832 Mouse studies suggest inhibiting CD73 could help to improve memory by regulating adenosine signaling in the brain through ADORA2A. Full Text | PDF Distillery: Techniques Assays and screens Top Human plasmablast enrichment to identify broadly neutralizing influenza A antibodies with high frequency doi:10.1038/scibx.2013.833 A strategy to enrich human plasmablasts could be used to identify broadly neutralizing influenza A antibodies with high frequency. Full Text | PDF In situ RNA sequencing in fixed cells and tissues doi:10.1038/scibx.2013.834 In situ RNA sequencing could help reveal genetic heterogeneity in complex samples for clinical diagnostics. Full Text | PDF Inner-ear hair cell cultures generated from embryonic stem cells (ESCs) as a screening platform for otology drugs doi:10.1038/scibx.2013.835 Inner-ear cell cultures generated from ESCs could help identify drug compounds that are ototoxic or promote inner-ear hair cell differentiation and regeneration. Full Text | PDF Disease models Top Dominant negative-disrupted in schizophrenia 1 (DISC1) mouse models of prefrontal cortex dysfunction doi:10.1038/scibx.2013.836 Mice expressing a dominant negative form of DISC1 (DN-DISC1) could help model cognitive disorders. Full Text | PDF Genetic duplication mouse model for a hypomyelinating disorder doi:10.1038/scibx.2013.837 Mice with an engineered genomic duplication at the proteolipid protein 1 (Plp1) locus could be useful for studying the hypomyelinating disorder Pelizaeus–Merzbacher disease (PMD). Full Text | PDF In vitro liver platform to model malaria infection doi:10.1038/scibx.2013.838 A hepatocyte culture model could be used to model liver-stage infection with Plasmodium falciparum or Plasmodium vivax. Full Text | PDF Mouse model of neonatal intracranial hemorrhage doi:10.1038/scibx.2013.839 A mouse model of neonatal intracranial hemorrhage could be useful for developing therapies for the condition. Full Text | PDF Drug platforms Top Blood vessels formed from induced pluripotent stem (iPS) cell–derived endothelial and mesenchymal stem cells doi:10.1038/scibx.2013.840 Mouse studies suggest that iPS cell–derived endothelial cells could regenerate vasculature to help treat cardiovascular diseases. Full Text | PDF Crystal structures of sirtuin 1 (SIRT1), SIRT2 and SIRT3 bound to inhibitors doi:10.1038/scibx.2013.841 Crystal structures of sirtuins bound to inhibitors could guide the development of compounds directed against specific sirtuins. Full Text | PDF Direct reprogramming of fibroblasts into induced hepatic stem cells (iHSCs) for liver regeneration doi:10.1038/scibx.2013.842 iHSCs derived directly from fibroblasts could help treat liver diseases. Full Text | PDF Generation of transplantable, vascularized liver buds from induced pluripotent stem (iPS) cells doi:10.1038/scibx.2013.843 Human vascularized liver buds grown in culture could be used to regenerate human livers and model liver disease. Full Text | PDF Single-dose RepliVax vaccine to prevent tick-borne encephalitis (TBE) doi:10.1038/scibx.2013.844 A single-cycle virus vaccine platform, RepliVax, could help generate vaccines to protect against TBE. Full Text | PDF Synthetic vascular networks derived from human pluripotent stem cells doi:10.1038/scibx.2013.845 In vitro and mouse studies suggest patient-specific synthetic vascular networks could be used for vascular regeneration. Full Text | PDF Top

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.